SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as community members rally behind its organic growth strategy, actively avoiding the typical pump-and-dump cycles associated with other meme tokens. Investors are showing strong conviction in the project's long-term potential, frequently discussing its lack of a chart as a badge of early-stage authenticity while pushing for increased volume to drive the next leg of upward momentum.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating significant community buzz as investors debate its long-term transactional utility against Bitcoin, with many keeping a close watch on potential catalysts like institutional adoption and integration with major platforms. Traders are currently split between viewing the asset as a prime short-squeeze opportunity and maintaining a cautious stance amidst broader market volatility.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community leans into its history as an original internet parody, positioning it as a cultural counter-narrative to traditional crypto assets. Discussions are dominated by debates over its long-term viability, with vocal supporters framing it as a multi-billion dollar opportunity while others dismiss the project as part of a wider trend of memetic absurdity.

ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

ICU Medical, Inc.

ICU Medical is trending as investors evaluate its integration of recent acquisitions and the company's long-term growth potential in the infusion systems and medical device market. The community remains focused on technical turnaround potential, management performance, and the company's ability to drive hospital adoption for its specialized device products.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is seeing significant trading activity as investors react to concerns over the impact of GLP-1 weight-loss drugs on the long-term demand for dialysis services. While the market has reacted sharply to clinical trial news from the obesity drug sector, analysts and community participants are actively debating whether this sell-off represents an overreaction or a fundamental shift in the kidney care landscape.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining momentum as the community rallies around its identity as a culture-driven project ahead of the 4/20 season, with supporters emphasizing its long-term focus on cannabis advocacy and decentralized community growth. Investors are actively discussing the potential impact of legislative developments like rescheduling, while contributors leverage the project's roots-first approach to distinguish it from transient meme coins.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch is trending as the community highlights its model of distributing Solana rewards to holders every six hours, positioning the token as a passive income play. Despite polarized debates regarding price performance and risks of retracement, bulls are actively focused on the project's long-term utility and recent infrastructure updates.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing heightened volatility and intense social debate, with bulls pointing to potential legislative catalysts like the Clarity Act and accumulation trends, while bears express deep skepticism, citing long-term price underperformance and dismissing the project as a cycle-dependent scam.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is capturing community attention as traders debate its potential for a massive breakout, fueled by frequent developer updates and a shift toward its role as an infrastructure layer for autonomous AI agents. While some investors are actively accumulating the token on dips, believing in its long-term utility and recent ecosystem expansion, others are urging caution due to the coin's historical volatility and the influence of broader market trends.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently trending as investors debate the potential for a renewed upward leg, with many pointing to the recent Canary Capital ETF filing as a major catalyst for institutional legitimacy. The community remains divided between those viewing the current volatility as a prime accumulation zone and others cautioning against meme coin cyclicality, while overall sentiment remains heavily tethered to broader Bitcoin and Ethereum market trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silo Pharma Rallies After Securing Key Patent Allowance

Silo Pharma shares are trading higher Tuesday after the EPO signaled intent to grant a patent for its serotonin 4 receptor stress application.read more...

Why Did SILO Stock Soar 85% Today? 

The European Patent Office granted a patent for the company’s novel 5-HT4 Post-Traumatic Stress Disorder (PTSD) prevention therapy.

Equity

The European Patent Office granted a patent for the company’s novel 5-HT4 Post-Traumatic Stress Disorder (PTSD) prevention therapy.


Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket

SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.read more...

Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline UnitedHealth, Silo Pharma, Phillips 66 In Focus

U.S. stocks rose on Tuesday, following Monday's advances.read more...

Levi Strauss, Greenbrier And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures down, investors should watch Levi Strauss, Silo Pharma, Greenbrier, Mach Natural Resources, and Phoenix Education Partners.read more...

Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know

Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.read more...

Silo Pharma's stock buzz increased on Wednesday after the company reported crucial development steps for SPC-15, their main product which serves as an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).&nbsp;Silo entered into a partnership with Frontage Laboratories to perform a 7-day significant animal safety and toxicology study as requested by the FDA.&nbsp;Shares of the company closed at $0.84 on Wednesday, down 23.3% for the day, and declined further by 4.9% to $0.80 in after-hours trading.Silo is moving forward with an IND-enabling Good Laboratory Practice (GLP)-compliant toxicology and toxicokinetic study focused on SPC-15.Completing the toxicology studies with favorable outcomes will enable the submission of an IND application in 2025.&nbsp;Silo intends to start a first-in-human Phase 1 clinical trial for SPC-15 after receiving approval.&nbsp;The pharma company has obtained an exclusive worldwide license from Columbia University to develop SPC-15 further and enable its manufacturing and commercial distribution.Additionally, Silo also partnered with Veloxity Labs to provide bioanalysis services for its current GLP toxicology and toxicokinetics research.&nbsp;The company confirmed its plan to start the FDA IND process for SPC-15 in 2025, with the goal of advancing to clinical trials once approval is obtained.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 3,300% surge in 24-hour message volume.One user mentioned that buying shares under a dollar has been consistently profitable for them over the past five years, though they plan to exit within three to six months, adding that catching pre-market price spikes requires early mornings.&nbsp;<stembedurl>https://stocktwits.com/Helson/message/614607172</stembedurl>Another user noted they took a 9% gain on the stock and planned to exit soon.<stembedurl>https://stocktwits.com/Bdport/message/614597364</stembedurl>The stock has declined 12% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment

The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.

After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025

Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.

Silo Pharma (SILO) isn't your typical market mover. But on Tuesday, this small-cap biopharma stock defied expectations, skyrocketing over 123% to become the undisputed champion of U.S. gainers. The secret weapon? An exclusive global license agreement for a promising Alzheimer's drug.Wednesday's pre-market trading painted a different picture as the stock fell by as much as 13%, suggesting some investors are taking profits after the wild ride. However, at around 11 am ET, shares had rebounded, gaining over 2%.<figure class="image"><img style="aspect-ratio:1322/756;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SILO_stock_move_Jul_17_c1ed653683.png" alt="SILO stock move Jul 17" width="1322" height="756"><figcaption>SILO stock move Jul 17</figcaption></figure>But hold on, the story doesn't end there. SILO is still capturing retail investor attention like never before. Stocktwits data reveals a surge in interest: the stock has the most new watchers in the past 24 hours, and follower counts have skyrocketed by a whopping 453% over the past week.The excitement stems from a licensing deal for SPC-14, an Alzheimer's drug currently in preclinical development. Silo Pharma plans to leverage the FDA's streamlined pathway, potentially speeding up clinical trials and reducing costs.&nbsp;With the global Alzheimer's treatment market expected to reach a staggering $30.8 billion by 2033, the potential is undeniable.Retail investors on Stocktwits are buzzing, bullish about the deal's potential to supercharge SILO's value. This comes on the heels of a similar licensing agreement for their lead drug candidate targeting stress and PTSD.&nbsp;With shares already up 57% year-to-date and hitting 11-month highs, the latest development could still trigger a retail frenzy for SILO over the longer-term, despite the pre-market dip.Representative <a href="https://pixabay.com/illustrations/neurons-brain-cells-brain-structure-7420662/">image</a> by Gerd Altmann from Pixabay

Why This Small-Cap Biopharma Is Getting The Most Retail Attention On Stocktwits Today

Silo Pharma’s shares more than doubled yesterday, driven by a promising new Alzheimer’s drug agreement.

Silo Pharma’s shares more than doubled yesterday as retail investors flock to the stock, driven by a promising new Alzheimer’s drug agreement.

This account has been verified as an official SILO representative.

Verified Account

Silo Pharma

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

Current Price	$0.441
Prev Close	$0.4159
Open	$0.3951
Dividend Yield	0.00%
50-Day Moving Average	$0.3432
Beta	0.89
Avg. Volume	217,758.04
PE Ratio	-0.73

52-Week High	$1.19
52-Week Low	$0.221
Market Capitalization	$6.25M
EPS (Annual)	-$0.5044
Price to Book	0.93
Revenue Per Employee	$24,034.00

SILO
SILO Pharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SILO News

SILOSILO Pharma Inc